MRNA Moderna146.41+9.79 (+7.2%)
MRNA Moderna152.98+12.64 (+9.0%)
Outlook is neutral, with stock confined to a span of ±10%
Strategy has +47% ROI potential and 6% overvalued
MRNA Moderna136.35-6.42 (-4.5%)